lilly glp-1 drugs drug analogs, new trend in obesity treatment, become even more effective < Pharma < Article Eli Lilly Weight-Loss Pill Shows – Eli Lilly, Novo Nordisk expand

The administration of cagrilintide, an extended-release amylin analog, in combination with semaglutide has shown average weight loss of 22.7% after 68 weeks of treatment in obese subjects compared to 15.7% weight loss with semaglutide alone, marking a 44% increase in weight loss efficacy compared to monotherapy, and putting it into a category of bariatric surgery alternatives

Neuropsychopharmacology 38, 437445

If the tumour appears to be stable, the monitoring can extend for years

Why it matters for body composition: Smaller fat cells mean less inflammation and better insulin sensitivity, two key components for losing fat while preserving muscle

My patients started asking about glutathione